RSS feed

Publications (original articles or review articles) published in 2022 from OUS - Department of Urology

18 publications found

Axcrona K, Aas K, Axcrona U, Skotheim RI (2022)
Re: Spatially Resolved Clonal Copy Number Alterations in Benign and Malignant Tissue
Eur Urol, 83 (2), 183
DOI 10.1016/j.eururo.2022.11.013, PubMed 36464529

Cai T, Privitera S, Trovato F, Capogrosso P, Dehò F, Cimino S, Rizzo M, Liguori G, Salonia A, Palmieri A, Verze P, Johansen TEB (2022)
A Proposal of a New Nomogram to Predict the Need for Testosterone ReplACEment (TRACE): A Simple Tool for Everyday Clinical Practice
J Pers Med, 12 (10)
DOI 10.3390/jpm12101654, PubMed 36294793

Cai T, Tamanini I, Collini L, Brugnolli A, Migno S, Mereu L, Tateo S, Pilatz A, Rizzo M, Liguori G, Bonkat G, Wagenlehner FME, Bjerklund Johansen TE (2022)
Management of Recurrent Cystitis in Women: When Prompt Identification of Risk Factors Might Make a Difference
Eur Urol Focus, 8 (5), 1476-1482
DOI 10.1016/j.euf.2022.01.014, PubMed 35135727

Christiansen O, Bratt O, Kirkevold Ø, Benth JŠ, Manoharan P, Selnes A, Haug ES, Slaaen M (2022)
Predictors of upgrading from low-grade cancer at prostatectomy in men with biparametric magnetic resonance imaging
Cent European J Urol, 75 (1), 35-40
DOI 10.5173/ceju.2021.0217, PubMed 35591966

Dahle DO, Skauby M, Langberg CW, Brabrand K, Wessel N, Midtvedt K (2022)
Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review
Transplantation, 106 (1), e52-e63
DOI 10.1097/TP.0000000000003762, PubMed 33741842

Galtung KF, Lauritzen PM, Baco E, Berg RE, Naas AM, Rud E (2022)
Predictive Performance of Prospectively Applied ISUP and Fuhrman Grade in Nonmetastatic Renal Cell Carcinoma
Anticancer Res, 42 (6), 2967-2975
DOI 10.21873/anticanres.15780, PubMed 35641263

Guldvik IJ, Braadland PR, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, Røder A, Schlomm T, Berge V, Eri LM, Lilleby W, Mills IG, Taskén KA (2022)
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
Eur Urol Open Sci, 45, 68-75
DOI 10.1016/j.euros.2022.09.002, PubMed 36353660

Günzel K, Magheli A, Busch J, Baco E, Cash H, Heinrich S, Edler D, Schostak M, Borgmann H, Schlegel J, Hinz S (2022)
Evaluation of systematic prostate biopsies when performing transperineal MRI/TRUS fusion biopsy with needle tracking-what is the additional value?
Int Urol Nephrol, 54 (10), 2477-2483
DOI 10.1007/s11255-022-03309-y, PubMed 35877030

Jacewicz M, Günzel K, Rud E, Sandbæk G, Magheli A, Busch J, Hinz S, Baco E (2022)
Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial
Lancet Infect Dis, 22 (10), 1465-1471
DOI 10.1016/S1473-3099(22)00373-5, PubMed 35839791

Luiting HB, Remmers S, Boevé ER, Valdagni R, Chiu PK, Semjonow A, Berge V, Tully KH, Rannikko AS, Staerman F, Roobol MJ (2022)
A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study
Eur Urol Oncol, 5 (6), 651-658
DOI 10.1016/j.euo.2022.03.007, PubMed 35437217

Møller CT, Fosså SD, Tafjord G, Babigumira R, Berge V, Andreassen BK (2022)
Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment
Scand J Urol, 56 (3), 214-220
DOI 10.1080/21681805.2022.2056633, PubMed 35506475

Møller CT, Støer NC, Blindheim A, Berge V, Tafjord G, Fosså SD, Andreassen BK (2022)
Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study
BMC Cancer, 22 (1), 1301
DOI 10.1186/s12885-022-10394-w, PubMed 36510166

Nilsen OJ, Holm HV, Ekerhult TO, Lindqvist K, Grabowska B, Persson B, Sairanen J (2022)
To Transect or Not Transect: Results from the Scandinavian Urethroplasty Study, A Multicentre Randomised Study of Bulbar Urethroplasty Comparing Excision and Primary Anastomosis Versus Buccal Mucosal Grafting
Eur Urol, 81 (4), 375-382
DOI 10.1016/j.eururo.2021.12.017, PubMed 35012771

Ouellet V, Erickson A, GAP1 UTMAs Contributing Investigators, Wiley K, Morrissey C, Berge V, Moreno CS, Tasken KA, Trudel D, True LD, Lewis MS, Svindland A, Ertunc O, Vidal ID, Osunkoya AO, Jones T, Bova GS, Lamminen T, Achtman AH, Buzza M, Kouspou MM, Bigler SA, Zhou X, Freedland SJ, Mes-Masson AM et al. (2022)
The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource
Cancer Epidemiol Biomarkers Prev, 31 (4), 715-727
DOI 10.1158/1055-9965.EPI-21-0600, PubMed 35131885

Pharo HD, Jeanmougin M, Ager-Wick E, Vedeld HM, Sørbø AK, Dahl C, Larsen LK, Honne H, Brandt-Winge S, Five MB, Monteiro-Reis S, Henrique R, Jeronimo C, Steven K, Wahlqvist R, Guldberg P, Lind GE (2022)
BladMetrix: a novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients
Clin Epigenetics, 14 (1), 115
DOI 10.1186/s13148-022-01335-2, PubMed 36115961

Rud E, Noor D, Galtung KF, Ottosson F, Jacewicz M, Baco E, Lauritzen PM (2022)
Validating the screening criteria for bone metastases in treatment-naïve unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases
Eur Radiol, 32 (12), 8266-8275
DOI 10.1007/s00330-022-08945-7, PubMed 35939081

Sivanesan S, Taskén KA, Grytli HH (2022)
Association of β-Blocker Use at Time of Radical Prostatectomy With Rate of Treatment for Prostate Cancer Recurrence
JAMA Netw Open, 5 (1), e2145230
DOI 10.1001/jamanetworkopen.2021.45230, PubMed 35080602

Tutone M, Bjerklund Johansen TE, Cai T, Mushtaq S, Livermore DM (2022)
SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study
Int J Antimicrob Agents, 59 (5), 106574
DOI 10.1016/j.ijantimicag.2022.106574, PubMed 35307561